RECRUITING

A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Talk to us

Conditions

Uterine Serous Carcinomauterusuterineendometrialendometriumserous carcinomawee1Wee-1uscserous

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).

Official Title

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma

Quick Facts

Study Start:2021-07-28
Study Completion:2025-05-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04814108

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Project Director
CONTACT
(858) 263-4333
medicalaffairs@zentalis.com

Principal Investigator

Project Director
STUDY_DIRECTOR
K-Group Beta (A wholly owned subsidiary of Zentalis Pharmaceuticals)

Study Locations (Sites)

Alaska Women's Cancer Care
Anchorage, Alaska, 99508
United States
Honor Health
Phoenix, Arizona, 85016
United States
Arizona Oncology Associates Wilmot HOPE
Tucson, Arizona, 85711
United States
University of California Irvine Medical Center
Orange, California, 92868
United States
University of California San Francisco at Mission Bay
San Francisco, California, 94158
United States
Mount Sinai Medical Center
Miami Beach, Florida, 33140
United States
Sarasota Memorial Hospital
Sarasota, Florida, 34239
United States
University of South Florida
Tampa, Florida, 33606
United States
Northside Hospital
Atlanta, Georgia, 30342
United States
Georgia Cancer Center at Augusta University
Augusta, Georgia, 30912
United States
Maryland Oncology Hematology
Annapolis, Maryland, 21401
United States
University of Maryland Medical Center
Baltimore, Maryland, 21201
United States
Corewell Health
Grand Rapids, Michigan, 49503
United States
Revive Clinical Research
Sterling, Michigan, 48659
United States
HCA Midwest Health Kansas City Research
Kansas City, Missouri, 64132
United States
Center of Hope
Reno, Nevada, 89511
United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901
United States
Optimum Clinical Research Group- Women's Oncology
Albuquerque, New Mexico, 87109
United States
Westchester Medical Center
Hawthorne, New York, 10532
United States
University of Cincinnati
Cincinnati, Ohio, 45219
United States
Oncology Hematology Care
Cincinnati, Ohio, 45242
United States
Trihealth Cancer Institute
Cincinnati, Ohio, 45242
United States
Ohio State University James Cancer Hospital
Columbus, Ohio, 43210
United States
University of Oklahoma Peggy and Charles Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104
United States
Willamette Valley Cancer Institute
Eugene, Oregon, 97401
United States
Providence Portland Medical Center
Portland, Oregon, 97213
United States
Northwest Cancer Specialists
Portland, Oregon, 97227
United States
Temple University Hospital
Philadelphia, Pennsylvania, 19140
United States
Ascension St. Thomas Midtown Hospital
Nashville, Tennessee, 37236
United States
Texas Oncology Austin
Austin, Texas, 78705
United States
Texas Oncology Fort Worth Cancer Center
Fort Worth, Texas, 76104
United States
Texas Oncology Gulf Coast
Houston, Texas, 77089
United States
Texas Oncology San Antonio
San Antonio, Texas, 78240
United States
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
United States
VCU Health System
Richmond, Virginia, 23298
United States
Virginia Cancer Specialists
Warrenton, Virginia, 20186
United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

  • Project Director, STUDY_DIRECTOR, K-Group Beta (A wholly owned subsidiary of Zentalis Pharmaceuticals)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-07-28
Study Completion Date2025-05-31

Study Record Updates

Study Start Date2021-07-28
Study Completion Date2025-05-31

Terms related to this study

Keywords Provided by Researchers

  • uterus
  • uterine
  • endometrial
  • endometrium
  • serous carcinoma
  • wee1
  • Wee-1
  • usc
  • Uterine Serous Carcinoma
  • serous

Additional Relevant MeSH Terms

  • Uterine Serous Carcinoma